Transgene

High-Risk Clinical Trials And Rising Costs Will Delay Returns Yet Unlock Value

AnalystLowTarget

Not Invested

Community Contributor

Published

14 Aug 25

Updated

14 Dec 25

Views

n/a

AnalystLowTarget's Fair Value

n/a

32.0%

8.4%

32.0%

8.4%

You can edit this narrative until Dec 15 9:10 PM. Then, changes will post as Updates.

Author's Valuation

€1.113.1% undervalued

AnalystLowTarget Fair Value

Narrative

Updates1

Shared on 14 Dec 25

Fair value Decreased 21%

TNG: Pipeline Progress And Stronger Balance Sheet Will Drive Future Upside

Analysts have moderately reduced their price target on Transgene, cutting fair value by about 20 percent to approximately 1.10 euros. They have incorporated slower expected revenue growth, a higher discount rate, and a more balanced, though significantly improved, long term profit margin outlook into their models.

AnalystLowTarget Fair Value

€1.1

13.1% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

34.60%

Biotech revenue growth rate

9.67%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

€3.42m

Earnings '28

52.12x

PE Ratio '28

€178.00m

Market Cap '28

€178.00m

Market Cap '28

134.26m

No. shares '28

€1.33

Share Price '28

€1.33 Share Price '28

Discounted to 2025 @ 6.49% p.a.

€1.10

Fair Value '25